title: Chemotherapy options for previously untreated acute myeloid leukemia.
abstract: BACKGROUND
  Intensive chemotherapy with cytarabine and an anthracycline for untreated acute myeloid leukemia (AML) has remained largely unchanged over the past 40 years, despite many large trials examining the choice and dosing of these agents.
  
  
  METHODS
  We will review the major published clinical trials for untreated AML that have established the dosing choice and schedule for intensive therapy, as well as trials for patients not eligible for more intensive therapy. We will also discuss treatment considerations for subgroups of patients.
  
  
  CONCLUSIONS
  While one or two cycles of anthracycline and cytarabine-based combination regimens remain the standard of care for younger and older patients with AML deemed fit to receive induction chemotherapy, controversy remains regarding the optimal selection and dosing schedule for anthracyclines. Low-intensity regimens, such as low-dose cytarabine and hypomethylating agents, can achieve a complete response even with adverse risk features, and can be used in a fit subset of older patients not eligible for clinical trial or transplant. Incorporation of new targeted agents, such as tyrosine kinase and small-molecule inhibitors, combined with better selection of drugs for unique patient cohorts, will likely be necessary to substantially improve outcomes in AML.
authors.affiliation: a Stanford University, Division of Hematology, Department of Medicine , Stanford, CA, USA brunom@stanford.edu.
authors.forename: Ryan C
authors.initials: RC
authors.lastname: Lynch
authors.affiliation: a Stanford University, Division of Hematology, Department of Medicine , Stanford, CA, USA brunom@stanford.edu.
authors.forename: Bruno C
authors.initials: BC
authors.lastname: Medeiros
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017326:Clinical Trials, Phase III as Topic; D003115:Colony-Stimulating Factors / Q000008:administration & dosage; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012074:Remission Induction
chemical_list: D003115:Colony-Stimulating Factors; D003561:Cytarabine; D003630:Daunorubicin
keywords: acute myeloid leukemia; cytarabine; daunorubicin; gemtuzumab ozogamicin; hypomethylating agents; idarubicin; induction chemotherapy; mitoxantrone